Other disorders of bile acid and cholesterol metabolism
Methodology & AI Transparency ⓘ
Other disorders of bile acid and cholesterol metabolism Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Other disorders of bile acid and cholesterol metabolism—coded clinically as E78.79 across Cholesterol & Lipids guidelines—combines coronary calcium risk in Other disorders of bile acid and cholesterol metabolism (E78.79: scoring) with structured follow-up of Fasting Triglycerides [Other disorders of bile acid and cholesterol metabolism E78.79] (< 100 mg/dL (E78.79)).
- 2 Real-world patient consensus: Diagnostic registry E78.79: Other disorders of bile acid and cholesterol metabolism is managed within Cholesterol & Lipids.
- 3 Typical cash cost range: Workup highlights for Other disorders of bile acid and cholesterol metabolism (E78.79): coronary calcium risk in Other disorders of bile acid and cholesterol metabolism (E78.79: scoring).
- 4 Top reported side effects / signs: Longitudinal Other disorders of bile acid and cholesterol metabolism monitoring tracks LDL Cholesterol [Other disorders of bile acid and cholesterol metabolism E78.79] toward < 85 mg/dL (E78.79).
Ask our AI Specialists anything about Other disorders of bile acid and cholesterol metabolism
What Is Other disorders of bile acid and cholesterol metabolism?
Other disorders of bile acid and cholesterol metabolism—coded clinically as E78.79 across Cholesterol & Lipids guidelines—combines coronary calcium risk in Other disorders of bile acid and cholesterol metabolism (E78.79: scoring) with structured follow-up of Fasting Triglycerides [Other disorders of bile acid and cholesterol metabolism E78.79] (< 100 mg/dL (E78.79)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Other disorders of bile acid and cholesterol metabolism (E78.79) center on remnant cholesterol accumulation [Other disorders of bile acid and cholesterol metabolism E78.79]. targeted cholesterol & lipids interventions aim to normalize LDL Cholesterol [Other disorders of bile acid and cholesterol metabolism E78.79].
Common Symptoms & Clinical Signs
- • Presentation of Other disorders of bile acid and cholesterol metabolism (E78.79): silent elevation of in Other disorders of bile acid and cholesterol metabolism (E78.79: LDL-C, ApoB100, or)
- • Secondary Other disorders of bile acid and cholesterol metabolism clinical sign: elevated triglyceride-to-HDL ratio [Other disorders of bile acid and cholesterol metabolism E78.79]
- • Symptom flares in Other disorders of bile acid and cholesterol metabolism correlating with LDL Cholesterol [Other disorders of bile acid and cholesterol metabolism E78.79] deviation outside < 85 mg/dL (E78.79)
- • Functional cholesterol & lipids impact requiring coronary calcium risk in Other disorders of bile acid and cholesterol metabolism (E78.79: scoring) evaluation (E78.79)
Other disorders of bile acid and cholesterol metabolism Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E78.79 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NLM Clinical Tables |
| Diagnostic / Lab Marker: LDL Cholesterol [Other disorders of bile acid and cholesterol metabolism E78.79] | < 85 mg/dL (E78.79) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Triglycerides [Other disorders of bile acid and cholesterol metabolism E78.79] | < 100 mg/dL (E78.79) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Lipoprotein(a) [Lp(a)] [Other disorders of bile acid and cholesterol metabolism E78.79] | < 75 nmol/L (E78.79) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other disorders of bile acid and cholesterol metabolism
Treatment selection for Other disorders of bile acid and cholesterol metabolism depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other disorders of bile acid and cholesterol metabolism)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other disorders of bile acid and cholesterol metabolism Patient Community & “People Like Me” Threads
Filter Other disorders of bile acid and cholesterol metabolism community threads and patient logs by age, biological sex, dosage, and treatment duration.